Literature DB >> 2345817

Vascular lesions in the biopsied bronchus of patients with sarcoidosis changes of the endothelial cells in aggregation of eosinophils.

I Mochizuki1, T Kobayashi, R Wada, T Kawaguchi, K Ozawa, M Fukushima, Y Hirose, H Kono, J Takeda, S Kusama.   

Abstract

1) Aggregates of eosinophils closely related to the enlarged endothelial cells in the capillary vessels were recognized in 64% of 28 cases in biopsied specimens of the major bronchus of patients with sarcoidosis. 2) Electron microscopy revealed the vacuolated central cores or matrix in the specific granules of the eosinophils adjacent to the swollen vascular endothelial cells, frequent findings with attachment of the blood platelets to the damaged plasma membrane of the endothelial cells eventually becoming occluded in the lumen with platelet thrombosis, and multilayer formation of the basement membrane of the capillary vessels. 3) Sarcoidosis is suggested to be a pathological process producing both granuloma formation in each organ and vascular endothelial cell changes in the capillary vessels accompanied by aggregation of eosinophils in some periods of the disease process due to unidentified etiological factors.

Entities:  

Mesh:

Year:  1990        PMID: 2345817

Source DB:  PubMed          Journal:  Sarcoidosis        ISSN: 0393-1447


  3 in total

Review 1.  Antiendothelial cell antibodies (AECA) in patients with uveoretinitis.

Authors:  C Edelsten; D P D'Cruz
Journal:  Clin Rev Allergy Immunol       Date:  1997       Impact factor: 8.667

2.  Experimental extrinsic allergic alveolitis and pulmonary angiitis induced by intratracheal or intravenous challenge with Corynebacterium parvum in sensitized rats.

Authors:  E S Yi; H Lee; Y K Suh; W Tang; M Qi; S Yin; D G Remick; T R Ulich
Journal:  Am J Pathol       Date:  1996-10       Impact factor: 4.307

Review 3.  Cardiac sarcoidosis: diagnostic, prognostic, and therapeutic considerations.

Authors:  M Sekiguchi; Y Yazaki; M Isobe; M Hiroe
Journal:  Cardiovasc Drugs Ther       Date:  1996-11       Impact factor: 3.727

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.